Identification of the Risk Factors for Recurrence of Stage III Colorectal Cancer

被引:13
作者
Neki, Kai [1 ]
Eto, Ken [1 ]
Kosuge, Makoto [1 ]
Ohkuma, Masahisa [1 ]
Ito, Daisuke [1 ]
Takeda, Yasuhiro [1 ]
Yatabe, Saori [1 ]
Sugano, Hiroshi [1 ]
Yanaga, Katsuhiko [1 ]
机构
[1] Jikei Univ, Dept Surg, Sch Med, Tokyo, Japan
关键词
Risk factors; colorectal cancer; stage III; TEGAFUR PLUS LEUCOVORIN; ADJUVANT TREATMENT; COLON-CANCER; INTRAVENOUS FLUOROURACIL; ORAL URACIL; OXALIPLATIN; CHEMOTHERAPY; SURVIVAL; RECOMMENDATIONS; THERAPY;
D O I
10.21873/anticanres.13772
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to identify risk factors for recurrence of patients with stage III colorectal cancer by assessing clinicopathological features. Patients and Methods: The study included 231 patients with stage III colorectal cancer who underwent curative resection between 2006 and 2012 at the Department of Surgery of the Jikei University Hospital, Tokyo, Japan. Clinicopathological data of the patients were retrospectively evaluated. Results: The recurrence rate was 27.7% (64/231) in the study group. The univariate analysis for recurrence identified five risk factors: site of primary tumor (rectal cancer), surgical procedure (open surgery), preoperative serum CEA level (>5 ng/ml), preoperative serum CA19-9 level (>37 U/ml), and number of metastatic lymph nodes (over three metastases). The multivariate analysis for recurrence identified three risk factors: rectal cancer, preoperative serum CEA level >5.0 ng/ml 95%, and more than three metastatic lymph nodes. Conclusion: The risk factors for stage III colorectal cancer recurrence seem to be rectal cancer, preoperative serum CEA level >5.0 ng/ml, and more than three metastatic lymph nodes.
引用
收藏
页码:5721 / 5724
页数:4
相关论文
共 15 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[3]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[4]   Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why? [J].
Bertero, Luca ;
Massa, Federica ;
Metovic, Jasna ;
Zanetti, Roberto ;
Castellano, Isabella ;
Ricardi, Umberto ;
Papotti, Mauro ;
Cassoni, Paola .
VIRCHOWS ARCHIV, 2018, 472 (04) :519-531
[5]   Adjuvant therapy in colon cancer - what, when and how? [J].
Chau, I. ;
Cunningham, D. .
ANNALS OF ONCOLOGY, 2006, 17 (09) :1347-1359
[6]   Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer [J].
Haller, Daniel G. ;
Tabernero, Josep ;
Maroun, Jean ;
de Braud, Filippo ;
Price, Timothy ;
Van Cutsem, Eric ;
Hill, Mark ;
Gilberg, Frank ;
Rittweger, Karen ;
Schmoll, Hans-Joachim .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) :1465-1471
[7]   Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07 [J].
Kuebler, J. Philip ;
Wieand, H. Samuel ;
O'Connell, Michael J. ;
Smith, Roy E. ;
Colangelo, Linda H. ;
Yothers, Greg ;
Petrelli, Nicholas J. ;
Findlay, Michael P. ;
Seay, Thomas E. ;
Atkins, James N. ;
Zapas, John L. ;
Goodwin, J. Wendall ;
Fehrenbacher, Louis ;
Ramanathan, Ramesh K. ;
Conley, Barbara A. ;
Flynn, Patrick J. ;
Soori, Gamini ;
Colman, Lauren K. ;
Levine, Edward A. ;
Lanier, Keith S. ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) :2198-2204
[8]   Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-06 [J].
Lembersky, BC ;
Wieand, HS ;
Petrelli, NJ ;
O'Connell, MJ ;
Colangelo, LH ;
Smith, RE ;
Seay, TE ;
Giguere, JK ;
Marshall, ME ;
Jacobs, AD ;
Colman, LK ;
Soran, A ;
Yothers, G ;
Wolmark, N .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2059-2064
[9]  
Ma Cheng-Jen, 2006, KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, V22, P604
[10]   Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: Final results of JCOG0205 [J].
Shimada, Yasuhiro ;
Hamaguchi, Tetsuya ;
Mizusawa, Junki ;
Saito, Norio ;
Kanemitsu, Yukihide ;
Takiguchi, Nobuhiro ;
Ohue, Masayuki ;
Kato, Takeshi ;
Takii, Yasumasa ;
Sato, Toshihiko ;
Tomita, Naohiro ;
Yamaguchi, Shigeki ;
Akaike, Makoto ;
Mishima, Hideyuki ;
Kubo, Yoshiro ;
Nakamura, Kenichi ;
Fukuda, Haruhiko ;
Moriya, Yoshihiro .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) :2231-2240